Fhit delocalizes Annexin A4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Gaudio, Eugenio ^a,b,c   Paduano, Francesco ^c   Spizzo, Riccardo ^d   Ngankeu, Apollinaire ^a   Zanesi, Nicola ^a   Gaspari, Marco ^c   Ortuso, Francesco ^c   Lovat, Francesca ^a   Rock, Jonathan ^a   Hill, Grace A ^a   Kaou, Mohamed ^a   Cuda, Giovanni ^c   Aqeilan, Rami I ^a,e   Alcaro, Stefano ^c   Croce, Carlo M ^a   Trapasso, Francesco ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FRAGILE HISTIDINE TRIAD PROTEIN; LIPOCORTIN 4; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; CELL PROLIFERATION; CHEMOSENSITIZATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSOL; DRUG POTENTIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG CANCER; MOUSE; NONHUMAN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; TUMOR REGRESSION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ACID ANHYDRIDE HYDROLASES; AMINO ACID SEQUENCE; ANIMALS; ANNEXIN A4; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MEMBRANE; CYTOSOL; GENE EXPRESSION; HUMANS; IMMUNOPRECIPITATION; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PACLITAXEL; PROTEIN TRANSPORT;

EID: 84892381951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078610     Document Type: Article

References (42)

1. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, et al. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-97.
2. Matsuyama A, Shiraishi T, Trapasso F, Kuroki T, Alder H, et al. (2003) Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic. Proc Natl Acad Sci USA 100: 14988-93.
3. Huebner K, Saldivar JC, Sun J, Shibata H, Druck T (2011) Hits, Fhits and Nits: beyond enzymatic function. Adv Enzyme Regul 51: 208-17.
4. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, et al. (1996) FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93: 9770-5.
5. D'Agostini F, Izzotti A, Balansky R, Zanesi N, Croce CM, et al. (2006) Early loss of Fhit in the respiratory tract of rodents exposed to environmental cigarette smoke. Cancer Res 66: 3936-41.
6. Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, et al. (1998) Loss of FHIT expression in gastric carcinoma. Cancer Res 58: 4708-14.
7. Hendricks DT, Taylor R, Reed M, Birrer MJ (1997) FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res 57: 2112-5.
8. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, et al. (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85: 17-26.
9. Bianchi F, Magnifico A, Olgiati C, Zanesi N, Pekarsky Y, et al. (2006) FHITproteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proc Natl Acad Sci USA 103: 18981-6.
10. Bianchi F, Tagliabue E, Ménard S, Campiglio M (2007) Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections. Cell Cycle 6: 643-6.
11. Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, et al. (2003) Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res 1: 940-7.
12. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, et al. (2001) The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98: 10250-5.
13. Zanesi N, Mancini R, Sevignani C, Vecchione A, Kaou M, et al. (2005) Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. Cancer Res 65: 6576-82.
14. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, et al. (2000) Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 97: 4742-7.
15. Ji L, Fang B, Yen N, Fong K, Minna JD, et al. (1999) Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59: 3333-9.
16. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, et al. (2001) Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 61: 1578-84.
17. Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, et al. (2001a) FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98: 3346-51.
18. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, et al. (2001b) Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 61: 4827-36.
19. Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, et al. (2003) Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res 63: 1183-7.
20. Pichiorri F, Trapasso F, Palumbo T, Aqeilan RI, Drusco A, et al. (2006) Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res 12: 3494-501.
21. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, et al. (1996) Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry 35: 11529-35.
22. Draganescu A, Hodawadekar SC, Gee KR, Brenner C (2000) Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates. J Biol Chem 275: 4555-60.
23. Trapasso F, Krakowiak A, Cesari R, Arkles J, Yendamuri S, et al. (2003) Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc Natl Acad Sci USA 100: 1592-7.
24. Pekarsky Y, Garrison PN, Palamarchuk A, Zanesi N, Aqeilan RI, et al. (2004) Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 101: 3775-9.
25. Semba S, Trapasso F, Fabbri M, McCorkell KA, Volinia S, et al. (2006) Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 25: 2860-72.
26. Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, et al. (2008) Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem 283: 13736-44.
27. Rimessi A, Marchi S, Fotino C, Romagnoli A, Huebner K, et al. (2009) Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis. Proc Natl Acad Sci USA 106: 12753-8.
28. Kim CH, Yoo JS, Lee CT, Kim YW, Han SK, et al. (2006) FHIT protein enhances paclitaxel-induced apoptosis in lung cancer cells. Int. J. Cancer 118: 1692-8.
29. Song J, Shih IeM, Salani R, Chan DW, Zhang Z (2007) Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 13: 6842-9.
30. Gerke V, Moss SE (2002) Annexins: From structure to function. Physiol Rev 82: 331-371.
31. Gerke V, Creutz CE, Moss SE (2005) Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6: 449-461.
32. Hayes MJ, Moss SE (2004) Annexins and disease. Biochem Biophys Res Commun 322: 1166-1170.
33. Hayes MJ, Longbottom RE, Evans MA, Moss SE (2007) Annexinopathies. Subcell Biochem 45: 1-28.
34. Rand J (2000) The annexinopathies: a new category of diseases. Biochim Biophys Acta 1498: 169-173.
35. Rescher U, Gerke V (2004) Annexins - unique membrane binding proteins with diverse functions. J Cell Sci 117: 2631-2639.
36. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC (2000) Modulation of paclitaxel resistance by annexin IV in human cancer cell line. British journal of cancer 83: 83-88.
37. Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, et al. (2004) Annexin-I expression modulates drug resistance in tumor cells. Biochem Biophys Res Commun 314: 565-70.
38. Ding S, Chamberlain M, McLaren A, Goh LB, Duncan I, et al. (2001) Crosstalk between signalling pathways and the multidrug resistant protein MDR-1. British Journal of Cancer 85: 1175-84.
39. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, et al. (2012) Tcl1 interacts with Atm and enhances NF-KB activation in hematological malignancies. Blood 119: 180-7.
40. Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, et al. (2013) Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood 121: 351-9.
41. Adriani F, Perego P, Carenini N, Roz L (2006) Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer. Neoplasia 8: 9-17.
42. Cortinovis DL, Andriani F, Livio A, Fabbri A, Perrone F, et al. (2008) FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. 8: 342-8.